Primary IgA Nephropathy (IgAN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Primary IgA Nephropathy (IgAN) Market Outlook

Thelansis’s “Primary IgA Nephropathy (IgAN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary IgA Nephropathy (IgAN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Primary IgA Nephropathy (IgAN) Overview

Primary IgA nephropathy is the most common primary glomerulonephritis globally, characterized by progressive renal impairment driven by glomerular deposition of galactose-deficient IgA1 immune complexes. Pathogenesis follows a multi-hit model where mesangial deposition triggers inflammation, glomerulosclerosis, and interstitial fibrosis, presenting clinically as hematuria, hypertension, and proteinuria. Diagnosis requires renal biopsy confirming dominant mesangial IgA deposition. Standard management pairs maximum-tolerated renin-angiotensin system inhibition with targeted therapies. Frontline disease-modifying care utilizes gut-targeted delayed-release budesonide to suppress antibody production in ileal lymphoid tissue, alongside sparsentan or the selective endothelin-A receptor antagonist atrasentan to reduce hemodynamic stress. Crucially, the therapeutic framework has expanded past these baseline approaches. The management of progressive disease is anchored by Voyxact (sibeprenlimab), an approved first-in-class selective APRIL inhibitor that directly blocks the signaling cascade driving abnormal IgA production. Furthermore, the alternative complement pathway is addressed with the approved oral factor B inhibitor Fabhalta (iptacopan) to halt downstream glomerular damage in high-risk patients. Conversely, lectin pathway options like the MASP-2 inhibitor narsoplimab remain purely investigational without regulatory approval. Vigilant long-term tracking of estimated glomerular filtration rates and protein excretion is necessary to delay structural degradation and avoid kidney failure.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026–2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Primary IgA Nephropathy (IgAN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036